LTP LTR Pharma Limited
Healthcare · Biotechnology
· website
$0.47
52wk 0.35 – 0.75
Overall
33.9
Value
59.7
Growth
0.0
Health
50.0
Quality
0.0
Momentum
57.4
Dividend
—
Price
About LTR Pharma Limited
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 5.6% |
| 1 month | -7.8% |
| 3 months | -13.8% |
| 6 months | 13.3% |
| 1 year | -29.9% |
| 3 years | — |
Risk
| Volatility (1y ann.) | 84.3% |
| Beta vs ASX 200 | 1.21 |
| Sharpe (1y) | -0.07 |
| VaR 95% (1-day) | -6.3% |
| Max drawdown (1y) | -50.7% |
| Off 1-year high | -34.7% |
Technicals
| RSI(14) | 54 |
| vs 50DMA | -1.4% |
| vs 200DMA | -2.8% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
59.7
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
52
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
50.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
57.4
6-month return vs ASX 200
100
Price vs 200-day average
41
Price vs 50-day average
43
Position in 52-week range
30
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$85.67M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.08
Dividend yield
—
Payout ratio
0.0%
Beta
2.18
EV / EBITDA
-4.70
Price / Book
4.23
ROE
-54.7%
Operating margin
-1,218.4%
Net margin
0.0%
Total cash
$19.66M
Total debt
$0
Current ratio
34.36
Debt / Equity
—
Free cash flow
$-6.51M
Avg volume
162,424
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$145.78K
- Gross profit$145.78K
- Operating income-$7.47M
- Net income-$5.59M
- Diluted EPS-0.03
- Free cash flow-$4.45M
- Net debt-$31.81M